



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI

THE LYMPHOMAS CONFERENCE

II EDITION

Presidents:

Gerardo Musuraca, Nicola Normanno

Scientific Secretariat:

Claudio Cerchione, Eliana Liardo,

Alessandro Lucchesi, Francesco Malaspina,

Giovanni Martinelli, Margherita Parolini,

Costantino Riemma, Jessica Rosa, Pietro Rossi

Promoted by

Unità Ematologia e Trapianti IRCCS IRST "Dino Amadori" Meldola

09-10
MAY
2025
ROME



A.ROMA LIFESTYLE HOTEL, ROME

Via Giorgio Zoega, 59

Organizing Secretariat



Registration

Download the “DEEP ECM” app on your smartphone.



Login or create a new account

Enter the event pin: **LYMPHOMAS25**

You are now on the event page, click on **“REGISTRATION”** at the top left

The Conference has been accredited to the Italian Ministry of Health:

Event n. 446818 Provider n. 2007

ECM Credits n. 9.1 for:

Medical Surgeon (interdisciplinary area), Biologist, Pharmacist, TSLB, Nurse

Training objective 3: Clinical documentation. Diagnostic and rehabilitation clinical-care pathways, care profiles - treatment profiles.

Each participant, to obtain ECM credits, must participate in at least 90% of the scientific work and complete the online ECM questionnaire with a total of 75% of correct answers.

Attendance will be registered via barcode reader.

Participation at the event is free of charge, but registration is compulsory.
The registration deadline is 01 May 2025



PROMOTED BY



**SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA**

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI

PATRONAGE



**ASSOCIAZIONE ITALIANA
CONTRO LEUCEMIE
LINFOMI E MIELOMA**



ASSOCIAZIONE
ITALIANA
ONCOLOGIA
MEDICA



**FONDAZIONE
ITALIANA
LINFOMI**



GITMO
GRUPPO ITALIANO PER LO STUDIO DEI TUMORI

SIE
**Società Italiana
di Ematologia**



FACULTY

ALINARI LAPO	OHIO STATE UNIVERSITY, COLUMBUS
AL SAWAF OTHMAN	UNIVERSITY HOSPITAL OF COLOGNE, COLONIA
BORCHMANN PETER	UNIVERSITY HOSPITAL OF COLOGNE, COLONIA
CERCHIONE CLAUDIO	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
CUNEO ANTONIO	AOU UO EMATOLOGIA, FERRARA
DALLA FAVERA RICCARDO	COLUMBIA UNIVERSITY, NEW YORK
DERENZINI ENRICO	IEO ISTITUTO EUROPEO DI ONCOLOGIA, MILANO
GINI GUIDO	UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA
LUCCHESI ALESSANDRO	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
LUMINARI STEFANO	UNIMORE, MODENA
MADDOCKS KAMI	OHIO STATE UNIVERSITY, COLUMBUS
MALASPINA FRANCESCO	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
MARTELLI MAURIZIO	UNIVERSITÀ LA SAPIENZA, ROMA
MARTINELLI GIOVANNI	ISTITUTO SERAGNOLI, BOLOGNA
MUSURACA GERARDO	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
NOWAKOWSKI GREG	MAYO CLINIC COMPREHENSIVE CANCER CENTER, ROCHESTER
PASQUALUCCI LAURA	COLUMBIA UNIVERSITY, NEW YORK
PIERINI ANTONIO	T.M.O AZIENDA OSPEDALIERA, PERUGIA
PILERI ALESSANDRO	IRCCS AOU S. ORSOLA, BOLOGNA
PINTO ANTONELLO	IRCCS ISTITUTO NAZIONALE TUMORI FONDAZIONE G. PASCALE, NAPOLI
RIEMMA COSTANTINO	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
ROSCHEWSKI MARK	NIH BETHESDA, MARYLAND



ROSSI DAVIDE	EOC SVIZZERA, BELLINZONA
ROSSI PIETRO	IRCCS IRST "DINO AMADORI", MELDOLA (FC)
SHIPP MARGARET	DANA FARBER HARVARD CANCER CENTER, BOSTON
SCHUSTER STEPHEN	ABRAMSON CANCER CENTER UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA
SILKENSTEDT ELISABETH	LMU KLINIKUM, MONACO DI BAVIERA
SOUSSAIN CAROLE	ISTITUT CURIE - HOPITAL RENÉ HUGUENIN, PARIGI
SUREDA ANNA	HOSPITAL UNIVERSITARI DEXEUS, BARCELLONA
TANI MONICA	OSPEDALE S. MARIA DELLE CROCI, RAVENNA
TEDESCHI ALESSANDRA	ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA
TOSI PATRIZIA	UO EMATOLOGIA AUSL RIMINI
TREON STEVEN	BING CENTER FOR WALDENSTROM'S MACROGLOBULINEMIA DFCI, BOSTON
VITOLO UMBERTO	IRCCS CANDIOLO (TO)
ZUCCA EMANUELE	EOC SVIZZERA, BELLINZONA

KEY INFORMATION

VENUE

A. ROMA LIFESTYLE HOTEL

Via Giorgio Zoega, 59, 00164 Roma, Italy

INTERNET

WiFi is available in all areas.



GENERAL INFORMATION

LANGUAGE

The official language during the congress is English, therefore, all presentations will be given in English.

CLIMATE

The average temperature is around 16–27 degrees.

BANKING SERVICE

The official currency in Rome is the Euro. Foreign currencies can be exchanged at banks, which are usually open from Monday to Friday from 08:30 to 13:30.

HOTEL INFORMATION

For hotel information and reservations please visit the Hotels & Groups Desk.

TAXI

The single number to call a taxi is 060609

For other utilities on the taxi service, see www.060608.it

The journey to/ from Fiumicino Airport: 48€

The journey to/ from Ciampino Airport: 30€

The rates from Termini railway station to the city centre should cost between € 8 - € 15.




PUBLIC TRANSPORT



Termini railway station is 10 km from the hotel.

The hotel is connected to the center of Rome by tram line no. 8. The nearest tram stop can be reached on foot from the hotel and the tram will take you directly to Piazza Venezia in 15-20 minutes.

A.Roma Lifestyle Hotel also offers a shuttle service to and from the city center, available from 8.30 to 21.00. Reservation required.



A detailed illustration of a cell, likely a eukaryotic cell, shown in cross-section. The cell is filled with various organelles, including a large nucleus with a prominent nucleolus, mitochondria, and other smaller vesicles. The cell is surrounded by other cells, some of which are partially visible in the background. The overall color scheme is dominated by blue and purple hues, giving it a scientific, microscopic appearance.

09
05.25

8:50 REGISTRATION

WELCOME AND INTRODUCTION

SESSION 1 • PART I

THE BIOLOGY OF THE DIFFUSE LARGE B CELL LYMPHOMA

Chairs: Giovanni Martinelli, Gerardo Musuraca

09:00-09:20 The pathways of Diffuse large B-cell lymphomas (DLBCL): Have we really arrived at the definitive classification for trials and clinics?
Margaret Shipp

09:20-09:40 Genetics of DLBCL : The past and the future
Riccardo Dalla Favera

09:40-10:00 Epigenetics control and dysregulation, TAD and friends
Laura Pasqualucci

10:00-10:20 Can AI Help Us Understand the Biology of DLBCL?
Francesco Malaspina

10:20-10:30 Round table: How can we integrate all the biology of DLBCL into a unifying biological model, for a unifying treatment model?
Dalla Favera, Malaspina, Martinelli, Musuraca, Pasqualucci, Shipp

10:30-10:50 *Coffee break*

SESSION 1 • PART II

DIFFUSE LARGE B CELL LYMPHOMA: TREATMENT STRATEGIES

Chairs: Greg Nowakowski, Umberto Vitolo

10:50-11:10 Current and future therapeutic approach in first line in DLBCL
Umberto Vitolo

11:10-11:30 Relapsed/refractory LBCL Lessons learned from CAR T and the current landscape
Stephen Schuster

Friday, May 09

11:30-11:50 Relapsed/refractory LBCL: The evolution of the CAR T cells
Lapo Alinari

11:50-12:20 Relapsed/refractory LBCL: Challenging “the Right Sequencing” in surfaces epitopes strategies (Bispecifics, Tafa Len, Lonca, Pola)
Gerardo Musuraca

12:20-12:40 The Fate of Elderly Patients: The Now That Will Change The Tomorrow
Guido Gini

12:40-13:00 DLBCL: Who is High risk and how should treatment be optimized: Strategies or molecules on the horizon
Greg Nowakowski

13:00-13:10 Round table: What is the future of treatment for diffuse large cell lymphoma?
Alinari, Gini, Musuraca, Nowakowski, Schuster, Vitolo

13.10-14.10 *Lunch*

Lunch Symposium NO ECM - with the contribution of ABBVIE (parallel room)
Chairman: Gerardo Musuraca

V+X: venetoclax as the backbone therapy in CLL
Alessandra Tedeschi

Delivering Complete Responses with subcutaneous epcoritamab for all R/R DLBCL patients
Enrico Derenzini

SESSION 2 • HODGKIN LYMPHOMA

Chairs : Peter Borchmann, Antonello Pinto, Claudio Cerchione

14:10-14:40 Comparing the “NOW”: What will be the “FUTURE” of the first-line treatment in Hodgkin lymphoma?

Antonello Pinto

14:40-15:10 Relapsed/refractory HL: something old, something new, Auto and Allo is there too?

Anna Sureda

15:10-15:40 How to treat elderly patients: new drugs, different story?

Peter Borchmann

15:40-15:50 **Round table: What is the Right Algorithm in Hodgkin lymphoma?**

Borchmann, Cerchione, Pinto, Sureda

15:50-16:10 *Coffee break*

SESSION • 3 MANTLE CELL LYMPHOMA

Chairs: Alessandro Lucchesi, Kami Maddocks

16:10-16:30 Mantle Cell Lymphomas' biology and pathology: step by step towards complexity and aggressivity

Elisabeth Silkenstedt

16:30-17:00 Risk-Based Approach to Mantle Cell Lymphoma: What we can do, what will do, on the frontline and beyond

Kami Maddocks

17:00-17:20 CAR T cells in MCL: Current landscape and future perspectives

Lapo Alinari

Friday, May 09

**SESSION 4 • MARGINAL ZONE LYMPHOMA AND WALDENSTROM
MACROGLOBULINEMIA**

Chairs: Davide Rossi, Emanuele Zucca

**17:20-17:50 Marginal zone Lymphoma: The biology of the disease and
how to approach first line**

Davide Rossi

**17:50-18:20 Marginal zone lymphoma: from second line to the future
strategies**

Emanuele Zucca

**18.20-18:50 Waldenstrom Macroglobulinemia: How to get out of the
diagnosis maze and what is the current and future treatment landscape**

Steven Treon

18.50 *Closing day remarks*

A microscopic view of several cells, each containing a cluster of red, spherical structures. The cells are translucent and blue-tinted, set against a light blue background. The red clusters are prominent and appear to be the focus of the image.

10

05.25

Saturday, May 10

SESSION 5 • CHRONIC LYMPHOCYTIC LEUKEMIA

Chairs : Antonio Cuneo, Othman Al Sawaf, Davide Rossi

09:00-09:20 Through the Maze of Biology: the Ariadne's Thread of Treatment's Choice

Davide Rossi

09:20-09:50 Choosing the right treatment in the right patient: First line and beyond

Othman Al Sawaf

09:50-10:10 High risk Chronic Lymphocytic Leukemia: All I can tell about it

Antonio Cuneo

10:10-10:30 New lands ahoy? Novel strategies in CLL

Costantino Riemma

10:30-10:40 Round table: How can we integrate the biology and the drugs into the right therapeutic sequencing?

Al Sawaf, Cuneo, Riemma, Rossi

10:40-11:00 *Coffee break*

SESSION 6 • FOLLICULAR LYMPHOMA

Chairs : Patrizia Tosi and Monica Tani

11:00-11:20 Dott Jekyll and Mr. Hide: Genetic drivers for transformation in Follicular lymphoma

Laura Pasqualucci

11:20-11:40 First line therapy: Now and next era

Pietro Rossi

11:40-12:00 CAR T cell: Which is the role in follicular lymphoma

Stephen Schuster

12:00-12:20 Relapse/refractory disease before and beyond CAR T

Stefano Luminari

12:20-13:10 **Lecture: Allograft in Lymphoma: Who, when and How**
Antonio Pierini

13:10-14:00 **Lunch**

SESSION 7 • SPECIAL TYPES OF LYMPHOMAS

Chairs : Enrico Derenzini, Maurizio Martelli, Carole Soussain

14:00-14:20 **Lecture: Primary large B cell lymphomas of immune privileged sites**
Mark Roschewski

14:20-14:50 Primary cutaneous lymphomas
Alessandro Pileri

14:50-15:10 Burkitt Lymphoma: a “dark” biology under the “starry sky” of the treatments
Mark Roschewski

15:10-15:40 T-cell lymphomas: From the biology to the treatments
Enrico Derenzini

15:40-16:00 Primary Mediastinal Diffuse large B cell lymphoma: A long and winding road...
Maurizio Martelli

16:00-16:30 Primary CNS Lymphoma: Everything you need to know
Carole Soussain

16:30-16:50 Double and triple hit lymphoma
Greg Nowakowski

16:50 **Closing remarks**
Gerardo Musuraca

SCIENTIFIC RATIONALE

The growing complexity of oncohematological pathologies and in particular in chronic lymphoproliferative syndromes and lymphomas, combined with the growing availability of new therapeutic opportunities, including immunotherapies, CAR T and new combinations on chronic lymphocytic leukemia, makes it essential to take the point of the care algorithm and experimental currently underway.

The second edition of this important meeting aims to compare professionals from all over the world on the most recent clinical and experimental practices implemented or to be implemented, on the most important and widespread lymphoma pathologies, in order to allow an improvement in the current knowledge of the physicians on the topics covered.

Furthermore, this should lead to a very high level cultural update on lymphoproliferative syndromes, with repercussions on the daily prescriptive appropriateness of individual Italian realities.

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM

GOLD

abbvie

SILVER

AstraZeneca 

Johnson & Johnson

Takeda

Roche

BRONZE

BeOne

Bristol Myers Squibb®

GILEAD


Kite

Incyte

Otsuka KIRIN


Lilly A MEDICINE COMPANY

sobi
rare strength



THE LYMPHOMAS CONFERENCE

II EDITION



**SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA**

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUT
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI

graphic design: Mario Titone